Member Info for undervaluedtoday

GOING2POP

3rd Resistance Point 2.263

2nd Resistance Point 2.130

1st Resistance Point 2.057

Last Price 2.455

Https://www.investing.com/news/company-news/faron-pharmaceuticals-receives-major-holding-notification-93CH-4622440

Https://www.proactiveinvestors.co.uk/companies/news/1090806/cellbxhealth-joins-forces-with-the-royal-marsden-on-lung-cancer-liquid-biopsy-study-1090806.html

Https://www.proactiveinvestors.co.uk/companies/news/1090824/cellbxhealth-shares-rise-8-on-royal-marsden-lung-cancer-collaboration-1090824.html

Mms have zilch stock to play with

Fantastic news no buy quotes all morning no surprise there looks like institutions have big orders in expecting more tr1s

Trinity Delta view: Cellbxhealth strategy centres on growing its Pharma Services as it seeks to widen commercial adoption of its proprietary Parsortix technology for CTC capture and subsequent downstream analysis. The marketing focus shifted a year ago towards the better-resourced large pharma customers where, despite more complex selling cycles, there is the potential to drive significant mid- and longer-term revenues. An analogous approach is addressing medtech diagnostics companies to support development of new assays and/or companion diagnostics. There is increasing clinical acceptance that CTC-driven diagnostics can provide complementary actionable information to current liquid biopsy methods, such as ctDNA, including invaluable additional insights that such methods alone cannot, our forecasts and valuation is £118m, or 37p per share.

The 3 analysts offering 12 month price targets for Cellbxhealth PLC have a median target of 17.00, with a high estimate of 30.00 and a low estimate of 4.00. The median estimate represents a 1,689.47% increase from the last price of 0.95.

https://markets.investorschronicle.co.uk/data/equities/tearsheet/forecasts?s=CLBX:LSE

20/04/2026 8:11am

Research Tree

CelLBxHealth has announced a research collaboration with The Royal Marsden NHS Foundation Trust, one of the world’s leading cancer centres, to evaluate the clinical utility of its CTC‑DNA technology in blood samples from patients with advanced lung cancer. The study targets a clearly defined and underserved patient cohort, those with uninformative ctDNA results, and represents an important validation step for CelLBxHealth’s proposition that CTC‑derived DNA

https://uk.advfn.com/stock-market/london/cellbxhealth-CLBX/share-news/Cavendish-CelLBxHealth-Study-collaboration-with-The-Royal-Marsden/98315052

Big week next week when they let buyers in

Jump into close

Nice finish

In big round numbers

Mega cash

Nice timing bro impossible getting a buy quote big rerate on the way

🫂😁💙

Ignore the noise as we go north fast when they let new investors in

Watch for chunky delayed buys mms need your stock get ready for games

I did say 10xbagger maybe more

Lets get this party moving